AbbVie Delays Generic Competition for Rinvoq, Boosts Sales Potential

AbbVie has secured a settlement with generic drugmakers, delaying the release of competing generic versions of its immunology drug, Rinvoq, until April 2037. Analysts forecast an average price target of $217.76 for the stock over the next year, with a potential upside of 2.89% based on the current trading price of $211.64. The consensus from 31 brokerage firms positions AbbVie as "Outperform."

AbbVie has secured a significant legal victory, extending the exclusivity of its blockbuster immunology drug, Rinvoq, until April 2037. The company has settled with all generic manufacturers that had filed applications with the FDA for generic versions of Rinvoq, effectively delaying the entry of competing generics into the U.S. market.

The settlement, announced on September 11, 2025, follows a lawsuit filed by AbbVie in late 2023 against several generic manufacturers, including Sandoz, Hetero Labs, Aurobindo Pharma, Intas Pharmaceuticals, and Sun Pharmaceuticals. AbbVie accused these companies of attempting to circumvent dozens of Rinvoq patents AbbVie in Settlement With Generic Drugmakers on Rinvoq -- Update^[1].

This development comes at a critical juncture for AbbVie, as it seeks to recover lost sales from its former mega-blockbuster, Humira, which lost patent protection in 2023. Rinvoq and its sibling drug, Skyrizi, have been pivotal in maintaining AbbVie's revenue growth, with analysts forecasting combined sales of $31 billion by 2027 AbbVie settles with generic Rinvoq hopefuls, shielding the immunology med's US stronghold until 2037^[2].

The extension of Rinvoq's exclusivity is expected to significantly impact the drug's sales trajectory. William Blair analysts previously anticipated a steep drop in Rinvoq sales starting in 2033, but now project peak worldwide sales of $19 billion in 2033 and peak U.S. sales of $15 billion in 2036 AbbVie in Settlement With Generic Drugmakers on Rinvoq -- Update^[1]. The analysts also note that upcoming Rinvoq approvals in conditions such as alopecia areata, vitiligo, hidradenitis suppurativa, and systemic lupus erythematosus could add an additional $2 billion to the drug's peak-year sales AbbVie settles with generic Rinvoq hopefuls, shielding the immunology med's US stronghold until 2037^[2].

AbbVie's stock has responded positively to the news, with shares increasing by nearly 4% on September 10, 2025. Analysts have set an average price target of $217.76 for the stock over the next year, with a potential upside of 2.89% based on the current trading price of $211.64 . The consensus from 31 brokerage firms positions AbbVie as "Outperform."

In conclusion, AbbVie's settlement with generic drugmakers not only delays the entry of competing generics but also provides a significant boost to the company's sales projections for Rinvoq. This development is a strategic win for AbbVie, positioning the company for continued growth in the immunology market.